(Q45260916)

11 December 2017

COX-2 selective inhibitors--important lessons learned (English)

1 reference

11 December 2017

1 reference

Simon R J Maxwell

1

1 reference

PubMed ID

15705439

11 December 2017

David J Webb

series ordinal

2

1 reference

PubMed ID

15705439

11 December 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

11 December 2017

1 reference

11 December 2017

365

1 reference

11 December 2017

9458

1 reference

11 December 2017

449-451

1 reference

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

11 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917876-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917876-3

1 reference

7 January 2021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917876-3

7 January 2021

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917876-3

7 January 2021

Risk of cardiovascular events associated with selective COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917876-3

7 January 2021

Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917876-3

7 January 2021

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917876-3

7 January 2021

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917876-3

7 January 2021

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917876-3

7 January 2021

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917876-3

7 January 2021

Prescribing in the UK

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917876-3

7 January 2021

Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917876-3

7 January 2021

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917876-3

7 January 2021

Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917876-3

7 January 2021

Time to register randomised trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917876-3

7 January 2021

10.1016/S0140-6736(05)17876-3

Identifiers

DOI

1 reference

11 December 2017

1 reference

PubMed ID

15705439